<DOC>
	<DOCNO>NCT00364845</DOCNO>
	<brief_summary>Treatment anemia associate chronic kidney disease ( CKD ) 36 week safety follow phase 52 week</brief_summary>
	<brief_title>STIMULATE Study : Anemia Correction Health-related Quality Life ( HRQoL ) Outcomes Elderly Chronic Kidney Disease ( CKD ) Patients</brief_title>
	<detailed_description>This multicentre , randomise , single-blind , placebo-controlled , two-arm parallel group study assess effect anaemia correction Hb maintenance darbepoetin alfa elderly CKD patient 36 week .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Stage 35 CKD dialysis Patients ≥ 70 year age Haemoglobin &lt; 110g/L screen Transferrin saturation ≥ 15 % screen Clinical history type 2 diabetes mellitus Anticipating schedule go renal replacement therapy next year , include renal transplant Uncontrolled hypertension two separate measurement screen Use erythropoietic protein within 12 week screen</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Quality Life</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Anemia</keyword>
</DOC>